Report cover image

Global Recombinant Human Coagulation Factor IX Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Publisher GlobalInfoResearch
Published Nov 28, 2025
Length 121 Pages
SKU # GFSH20612059

Description

According to our (Global Info Research) latest study, the global Recombinant Human Coagulation Factor IX market size was valued at US$ 580 million in 2024 and is forecast to a readjusted size of USD 743 million by 2031 with a CAGR of 3.5% during review period.

In this report, we will assess the current U.S. tariff framework alongside international policy adaptations, analyzing their effects on competitive market structures, regional economic dynamics, and supply chain resilience.

Recombinant human coagulation factor IX is a drug produced by genetic recombination technology, mainly used to treat hemophilia B (i.e. congenital coagulation factor IX deficiency). Its function is to supplement the coagulation factor IX that is lacking in the patient's body to help control and prevent bleeding. The drug is a colorless and clear solution after reconstitution. It is suitable for daily bleeding management and perioperative management of hemophilia B patients, but is not suitable for the treatment of other types of coagulation factor deficiency or conditions related to the anticoagulant effect of coumarin.

This report is a detailed and comprehensive analysis for global Recombinant Human Coagulation Factor IX market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Recombinant Human Coagulation Factor IX market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2020-2031

Global Recombinant Human Coagulation Factor IX market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2020-2031

Global Recombinant Human Coagulation Factor IX market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2020-2031

Global Recombinant Human Coagulation Factor IX market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Recombinant Human Coagulation Factor IX

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Recombinant Human Coagulation Factor IX market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Grifols, Biogen, Octapharma, Baxter, Cusabio, Sanofi, Cayman, NovoPro Bioscience, Sino Biological, Bio-Techne, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Recombinant Human Coagulation Factor IX market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
250 IU/Bottle
500 IU/Bottle
1000 IU/Bottle
2000 IU/Bottle

Market segment by Application
Adult Patients
Child Patients

Major players covered
Grifols
Biogen
Octapharma
Baxter
Cusabio
Sanofi
Cayman
NovoPro Bioscience
Sino Biological
Bio-Techne
IDELVION
Hualan Bio
Shuyang
ChinaBiologic
Diagbio

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Recombinant Human Coagulation Factor IX product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Recombinant Human Coagulation Factor IX, with price, sales quantity, revenue, and global market share of Recombinant Human Coagulation Factor IX from 2020 to 2025.

Chapter 3, the Recombinant Human Coagulation Factor IX competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Recombinant Human Coagulation Factor IX breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Recombinant Human Coagulation Factor IX market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Recombinant Human Coagulation Factor IX.

Chapter 14 and 15, to describe Recombinant Human Coagulation Factor IX sales channel, distributors, customers, research findings and conclusion.

Table of Contents

121 Pages
1 Market Overview
2 Manufacturers Profiles
3 Competitive Environment: Recombinant Human Coagulation Factor IX by Manufacturer
4 Consumption Analysis by Region
5 Market Segment by Type
6 Market Segment by Application
7 North America
8 Europe
9 Asia-Pacific
10 South America
11 Middle East & Africa
12 Market Dynamics
13 Raw Material and Industry Chain
14 Shipments by Distribution Channel
15 Research Findings and Conclusion
16 Appendix
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.